PRECISION MEDICINE STARTUP INTI LABS SETS SIGHTS ON GLOBAL INFERTILITY TREND
The company offers innovative and accessible diagnostic solutions that improve IVF success rates
Palo Alto, California: Inti Labs, Inc. (Inti Labs) today announces its official launch and ambitious long-term vision to overcome infertility. The company is focused on developing a range of first-in-class diagnostic tests for the in vitro fertilization (IVF) market. Their tests are aimed at reducing the number of IVF treatment cycles a patient must go through to become pregnant, easing the financial burden on families and increasing the turnover of fertility clinics.
The global fertility rate has steadily declined over the years, as more women delay motherhood. Those who choose to have children later often must rely on assisted reproductive technology (ART) such as IVF. While the technology has seen significant improvement in recent years, most women must still go through multiple IVF treatment cycles to obtain a viable pregnancy. In the US, a single IVF treatment cycle can cost over $20,000 and is rarely covered by insurance.
Ambitious to lead the IVF diagnostic market, Inti Labs has launched with its award-winning endometrial status test, MIRA®, already in use at more than 70 institutions worldwide, with ongoing expansion across Europe, the US and Southeast Asia. MIRA® uses unique miRNA biomarkers to identify a woman’s window of implantation (WOI), the optimal time for embryo transfer. About 30% of women suffering from infertility have a displaced WOI, which, if not factored in during an IVF treatment cycle, can lead to an unsuccessful pregnancy.
"Genetic detection technology in reproductive medicine is a new application of precision medicine,” said Inti Labs CEO Dr. Eric Yang. “Already we’re seeing a significant increase in the IVF success rate with MIRA® patients who match certain criteria. We’re excited to use this new technology to help more women have successful pregnancies."
Among those joining Inti Labs’ team is Barry Behr, Ph.D., H.C.L.D., fulfilling the role of Chief Technology Officer (CTO). Dr. Behr is a Stanford University Professor Emeritus, where he served as Director of the IVF Laboratory and Professor of Obstetrics and Gynecology. A leading expert in the IVF field, his embryo research has directly led to improved implantation and pregnancy rates.
With MIRA®’s promising early success and other tests nearing the prototype phase, Inti Labs believes IVF will become increasingly reliable and accessible to women across the globe, as we work towards a future where infertility is no longer an insurmountable obstacle.
---
For more information about Inti Labs, please contact:
Jesse Prent
Brand Marketing Director, Inti Labs
(438) 405-1050
jesse@intilabs.com